Biosergen
Sweden - SolnaBiotechnology
Focus: Biosergen is a Swedish biotechnology company founded in 2021 focused on antifungal therapies targeting neurology and infectious diseases. As a publicly traded biotech, the company operates in a specialized therapeutic niche with limited disclosed commercial footprint.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Biosergen
AI assessmentNot HiringNo open roles listed right now. Follow Biosergen to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BSG005 or placebo
Invasive Fungal InfectionsClinical Trials (1)
NCT04921254A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.
Phase 1Help build intelligence for Biosergen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.